Previous Close | 23.37 |
Open | 23.37 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's Range | 23.37 - 23.37 |
52 Week Range | 20.64 - 27.15 |
Volume | |
Avg. Volume | 191 |
Market Cap | 5.228B |
Beta (5Y Monthly) | 0.45 |
PE Ratio (TTM) | 27.49 |
EPS (TTM) | 0.85 |
Earnings Date | N/A |
Forward Dividend & Yield | 0.72 (3.07%) |
Ex-Dividend Date | Mar 21, 2024 |
1y Target Est | N/A |
In order to justify the effort of selecting individual stocks, it's worth striving to beat the returns from a market...
Merck has received a letter that Hikma Pharmaceuticals US unit has sought a pre-patent expiry approval from the US FDA to sell a generic version of its Bridion injection, the drugmaker said in filing on Monday. Merck said, on Feb. 5, it received the letter under the Hatch-Waxman Act, through which a company can seek FDA approval to market a copycat before the expiration of patents related to the brand-name drug. Merck said in the filing that it is currently considering its options.
Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, today welcomed Dr. Rahul Gupta, Director of the White House Office of National Drug Control Policy (ONDCP), to its Columbus, Ohio manufacturing facility for a visit and important dialogue on the US opioid overdose epidemic and Hikma's and ONDCP's shared goal of expanding the availability and awareness of life-saving naloxone.